Back to mobile site

Goldman Sachs Downgrades Evolent Health (EVH) to Neutral

June 5, 2020 6:39 AM EDT Send to a Friend
Goldman Sachs analyst Robert Jones downgraded Evolent Health (NYSE: EVH) from Buy to Neutral with a price target of $8.00.The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login